April 21 | 2022

Notice of annual general meeting of 2cureX AB (publ)

Read more
April 21 | 2022

Kallelse till årsstämma i 2cureX AB

Read more
April 21 | 2022

Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.

Read more
April 14 | 2022

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Read more
March 15 | 2022

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Read more
March 14 | 2022

2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022

Read more
February 24 | 2022

2cureX offentliggör delårsrapport för det fjärda kvartalen och alla tolv månader 2021

Read more
February 24 | 2022

2cureX publishes interim report for the fourth quarter and all 12 months of 2021

Read more
February 23 | 2022

2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.

Read more
February 23 | 2022

2cureX reorganizes to an even stronger distributor focus

Read more
January 21 | 2022

New Institutional shareholder

Read more
January 11 | 2022

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica

Read more
January 5 | 2022

IndiTreat® to be distributed in Poland by Perlan Technologies

Read more
December 22 | 2021

First IndiTreat® order received from Labormed, Slovenia

Read more
December 16 | 2021

First hospital joins the IndiTreat® Evaluation Program IGNITE

Read more
December 14 | 2021

2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment

Read more
December 13 | 2021

2cureX reaches the goals for the 2021 rollout plan

Read more
December 9 | 2021

2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey

Read more